Fusion protein for inhibiting angiogenesis

• Main Authors: WANG XIN, LI WENBO, SHI YANBIN, HOU YINGGANG, BAI LU, WANG RUYUE, DUAN JIANGONG, ZHANG HANZI, SONG MEIJUAN, WANG MEIZHU, GUO DINGDING, LI KAIKE, LI YANG, LI HONGYU, ZHANG QIAN, LI TING, LIU YIYAO, XIA RUNJIE
• Format: Patent
• Language: Chinese; English
• Published: 31.05.2022
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS THEREOF; CULTURE MEDIA; ENZYMOLOGY; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; ORGANIC CHEMISTRY; PEPTIDES; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROCESSES USING MICROORGANISMS; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; VINEGAR; WINE

The invention discloses a fusion protein for inhibiting angiogenesis, belongs to the field of genetic engineering pharmacy, and particularly relates to a fusion protein capable of serving as an angiogenesis inhibitor. The fusion protein has a long-acting angiogenesis inhibition effect, and according to the technical scheme disclosed by the invention, on one hand, the anti-angiogenesis activity of the angiogenesis endostatin and the melanoma inhibition effect are improved, on the other hand, the half-life period of the angiogenesis endostatin is prolonged, and the stability is further enhanced. 本发明公开了一种抑制血管生成的融合蛋白，属于基因工程制药领域，具体涉及一种能够作为血管生成抑制剂的融合蛋白。该融合蛋白具有长效的抑制血管生成作用，本发明公开的技术方案一方面提高了血管生成内皮抑素的抗血管生成活性及对黑色素瘤的抑制效果，另一方面又延长其半衰期，进一步增强了稳定性。